Trial Profile
Prospective Comparison of an ARNI With an ACE Inhibitor on enDOthelial Function by Brachial Artery Reactivity (PARADOR)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PARADOR
- 09 Oct 2018 Planned End Date changed from 1 Nov 2019 to 1 Aug 2019.
- 09 Oct 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Aug 2019.
- 09 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.